Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology

Biotechnology Journal

Volumn 10, Issue 9, 2015, Pages 1329-1344

  Rodrigues, Ana F ^a   Soares, Hugo R ^a,b   Guerreiro, Miguel R ^a,b   Alves, Paula M ^a,b   Coroadinha, Ana S ^a,b  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

Cell lines; Cell substrates; Chimeric vaccines; Viral vaccines; Virus like particles

Indexed keywords

CELL CULTURE; CELLS; CYTOLOGY; DESIGN; MANUFACTURE; METABOLISM; SUBSTRATES; VACCINES; VIRUSES;

ANIMAL CELLS; CELL LINES; CELL SUBSTRATES; CREATIVE IDEAS; GLOBAL HEALTH; INFECTIOUS AGENTS; SAFETY REQUIREMENTS; VIRUS-LIKE PARTICLES;

CELL ENGINEERING;

DIPLOID CELL VACCINE; DNA VACCINE; HEPATITIS A VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; RECOMBINANT ANTIGEN; ROTAVIRUS VACCINE; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

CELL ENGINEERING; CELL LINE; CELL METABOLISM; DRUG DESIGN; HUMAN; HYBRID; INOCULATION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS LIKE AGENT; PROCEDURES; TRENDS; VIRUS DISEASES;

HUMANS; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 84940592766     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400387     Document Type: Review

References (134)

1. Nabel, G. J., Designing tomorrow's vaccines. N. Engl. J. Med. 2013, 368, 551-560.
2. World Health Organization, Global Alliance for Vaccines and Immunization (GAVI) Fact sheet 169, revised March 2001, http://www.who.int/mediacentre/factsheets/fs169/en.
3. Ehreth, J., The value of vaccination: A global perspective. Vaccine 2003, 21, 4105-4117.
4. McCollum, A. M. et al., Poxvirus viability and signatures in historical relics. Emerg. Infect. Dis. 2014, 20, 177-184.
5. Riedel, S., Edward Jenner and the history of smallpox and vaccination. Proc. Bayl. Univ. Med. Cent. 2005, 18, 21-25.
6. Bonanni P. S. J., Vaccine evolution, in: Garçon, N., Stern, P. L., Cunningham, A. L., Stanberry, L. R. (Eds.), Understanding Modern Vaccines: Perspectives in Vaccinology, Elsevier 2011, pp. 1-24.
7. Weller, T. H., Robbins, F. C., Enders, J. F., Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proc. Soc. Exp. Biol. Med. 1949, 72, 153-155.
8. Plotkin, S. A., Vaccines: Past, present and future. Nat. Med. 2005, 11, (Suppl.) S5-S11.
9. Jungers, P., Chauveau, P., Courouce, A. M., Devillier, P. et al., Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients J. Infect. Dis. 1994, 169, 399-402.
10. Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G. et al., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356, 1928-1943.
11. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., Schiller, J. T., Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 12180-12184.
12. Nicholson, K. G., Influenza and vaccine development: A continued battle. Expert Rev. Vaccines 2009, 8, 373-374.
13. World Health Oranisation, The relathionship between persisting spinal paralysis and poliomyelites vaccine - results of a ten-year enquiry. Bull. World Health Organ. 1982, 60, 231-242.
14. Hoft, D. F., Leonardi, C., Milligan, T., Nahass, G. T. et al., Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin. Infect. Dis. 1999, 28, 785-790.
15. Strugnell, R., Zepp, F., Cunningham, A., Tantawichien, T., Vaccine antigens, in: Garçon, N., Stern, P. L., Cunningham, A. L., Stanberry, L. R. (Eds.), Understanding Modern Vaccines: Perspectives in Vaccinology, Elsevier 2011, pp. 61-88.
16. Clark, H. F., Offit, P. A., Plotkin, S. A., Heaton, P. M., The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr. Infect. Dis. J. 2006, 25, 577-583.
17. Men, R., Bray, M., Clark, D., Chanock, R. M., Lai, C. J., Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 1996, 70, 3930-3937.
18. Mueller, S., Papamichail, D., Coleman, J. R., Skiena, S., Wimmer, E., Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 2006, 80, 9687-9696.
19. Baxter, D., Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. (London) 2007, 57, 552-556.
20. Levine, M. M., Lagos, R., Esparza, J., Vaccines and vaccination in historical perspective, in: Levine, M. M. (Ed.), New Generation Vaccines, Marcel Dekker, Inc Ed. 1997, pp. 1-19.
21. Hepatitis B vaccines prepared from yeast by recombinant DNA techniques: Memorandum from a WHO meeting. Bull. WHO 1985, 63, 57-61.
22. Cox, M. M., Hollister, J. R., FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37, 182-189.
23. Kushnir, N., Streatfield, S. J., Yusibov, V., Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31, 58-83.
24. Ludwig, C., Wagner, R., Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007, 18, 537-545.
25. Grgacic, E. V., Anderson, D. A., Virus-like particles: Passport to immune recognition. Methods 2006, 40, 60-65.
26. Liu, M. A., DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011, 239, 62-84.
27. Davis, B. S., Chang, G. J., Cropp, B., Roehrig, J. T. et al., West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays J. Virol. 2001, 75, 4040-4047.
28. Purcell, M. K., Nichols, K. M., Winton, J. R., Kurath, G. et al., Comprehensive gene expression profiling following DNA vaccination of rainbow trout against infectious hematopoietic necrosis virus. Mol. Immunol. 2006, 43, 2089-2106.
29. Bellier, B., Klatzmann, D., Virus-like particle-based vaccines against hepatitis C virus infection. Expert Rev. Vaccines 2013, 12, 143-154.
30. Li, T., Lin, H., Zhang, Y., Li, M. et al., Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine 2014, 32, 1921-1931.
31. Subbarao, K., Matsuoka, Y., The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013, 21, 350-358.
32. Thompson, C. M., Petiot, E., Lennaertz, A., Henry, O., Kamen, A. A., Analytical technologies for influenza virus-like particle candidate vaccines: Challenges and emerging approaches. Virol. J. 2013, 10, 141.
33. Jariyapong, P., Xing, L., van Houten, N. E., Li, T. C. et al., Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine 2013, 31, 417-424.
34. Rivera-Hernandez, T., Hartas, J., Wu, Y., Chuan, Y. P. et al., Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 2013, 31, 1950-1955.
35. Skrastina, D., Petrovskis, I., Petraityte, R., Sominskaya, I. et al., Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein. Clin. Vaccine Immunol 2013, 20, 1719-1728.
36. Billaud, J. N., Peterson, D., Barr, M., Chen, A. et al., Combinatorial approach to hepadnavirus-like particle vaccine design J. Virol. 2005, 79, 13656-13666.
37. Schellenbacher, C., Kwak, K., Fink, D., Shafti-Keramat, S. et al., Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J. Invest. Dermatol. 2013, 133, 2706-2713.
38. Visciano, M. L., Diomede, L., Tagliamonte, M., Tornesello, M. L. et al., Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine 2011, 29, 4903-4912.
39. Chua, A. J., Vituret, C., Tan, M. L., Gonzalez, G. et al., A novel platform for virus-like particle-display of flaviviral envelope domain III: Induction of Dengue and West Nile virus neutralizing antibodies. Virol. J. 2013, 10, 129.
40. Coroadinha, A. S., Gama-Norton, L., Amaral, A. I., Hauser, H. et al., Production of retroviral vectors: Review. Curr. Gene Ther. 2010, 10, 456-473.
41. Garrone, P., Fluckiger, A. C., Mangeot, P. E., Gauthier, E. et al., A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 2011, 3, 94ra71.
42. Rodrigues, A. F., Guerreiro, M. R., Santiago, V. M., Dalba, C. et al., Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: Tailoring vector composition. Biotechnol. Bioeng. 2011, 108, 2623-2633.
43. Rodrigues, A. F., Guerreiro, M. R., Castro, R., Tomás, H. et al., Down-regulation of CD81 in human cells producing HCV-E1/E2 retroVLPs. BMC Proc. 2011, 5, 8 72.
44. Wang, W., Chen, X., Xue, C., Du, Y. et al., Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein. Vaccine 2012, 30, 7072-7077.
45. Watson, D. J., Kobinger, G. P., Passini, M. A., Wilson, J. M. et al., Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 2002, 5, 528-537.
46. Shen, H., Xue, C., Lv, L., Wang, W. et al., Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease. Virus Res. 2013, 178, 430-436.
47. Blaney, J. E., Marzi, A., Willet, M., Papaneri, A. B. et al., Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013, 9, e1003389.
48. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N. et al., Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191, 654-665.
49. Hammonds, J., Chen, X., Fouts, T., DeVico, A. et al., Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 2005, 79, 14804-14814.
50. Horowitz, E. D., Weinberg, M. S., Asokan, A., Glycated AAV vectors: Chemical redirection of viral tissue tropism. Bioconjug. Chem. 2011, 22, 529-532.
51. Goyvaerts, C., De Groeve, K., Dingemans, J., Van Lint, S. et al., Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther. 2012, 19, 1133-1140.
52. Kaliberov, S. A., Kaliberova, L. N., Buggio, M., Tremblay, J. M. et al., Adenoviral targeting using genetically incorporated camelid single variable domains. Lab. Invest. 2014, 94, 893-905.
53. Kitai, Y., Fukuda, H., Enomoto, T., Asakawa, Y. et al., Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor. J. Biotechnol. 2011, 155, 251-256.
54. Zhao, Q., Chen, W., Chen, Y., Zhang, L. et al., Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug. Chem. 2011, 22, 346-352.
55. Shi, X., Li, C., Gao, S., Zhang, L. et al., Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles. Colloids Surf., B 2014, 122, 498-504.
56. Huret, C., Desjardins, D., Miyalou, M., Levacher, B. et al., Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine 2013, 31, 1540-1547.
57. Jain, S., Patrick, A. J., Rosenthal, K. L., Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. Vaccine 2010, 28, 7070-7080.
58. Wang, B. Z., Xu, R., Quan, F. S., Kang, S. M. et al., Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 2010, 5, e13972.
59. Wu, D. T., Roth, M. J., MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors. Biomaterials 2014, 35, 8416-8426.
60. Keswani, R., Su, K., Pack, D. W., Efficient in vitro gene delivery by hybrid biopolymer/virus nanobiovectors. J. Control Release 2014, 192, 40-46.
61. Mendez, N., Herrera, V., Zhang, L., Hedjran, F. et al., Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency. Biomaterials 2014, 35, 9554-9561.
62. Sheppard, N. C., Brinckmann, S. A., Gartlan, K. H., Puthia, M. et al., Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. Int. Immunol. 2014, 26, 531-538.
63. McKee, S. J., Young, V. L., Clow, F., Hayman, C. M. et al., Virus-like particles and alpha-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. J. Control Release 2012, 159, 338-345.
64. Astray, R. M., Ventini, D. C., Boldorini, V. L., Silva, F. G. et al., Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors. Vaccine 2014, 32, 2829-2832.
65. Boettler, T., Cunha-Neto, E., Kalil, J., von Herrath, M., Can an immune-regulatory vaccine prevent HIV infection? Expert Rev. Anti Infect. Ther. 2012, 10, 299-305.
66. Gantier, M. P., Tong, S., Behlke, M. A., Irving, A. T. et al., Rational design of immunostimulatory siRNAs. Mol. Ther. 2010, 18, 785-795.
67. Esaki, M., Godoy, A., Rosenberger, J. K., Rosenberger, S. C. et al., Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. Avian Dis. 2013, 57, 750-755.
68. Morelli, A. E., Larregina, A. T., Ganster, R. W., Zahorchak, A. F. et al., Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J. Virol. 2000, 74, 9617-9628.
69. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J. et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209-2220.
70. Barouch, D. H., Novel adenovirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS 2010, 5, 386-390.
71. Bellier, B., Dalba, C., Clerc, B., Desjardins, D. et al., DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24, 2643-2655.
72. Bellier, B., Huret, C., Miyalou, M., Desjardins, D. et al., DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27, 5772-5780.
73. Lescaille, G., Pitoiset, F., Macedo, R., Baillou, C. et al., Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum. Gene Ther. 2013, 24, 533-544.
74. Ljungberg, K., Whitmore, A. C., Fluet, M. E., Moran, T. P. et al., Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J. Virol. 2007, 81, 13412-13423.
75. Epstein, S. L., Price, G. E., Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 2010, 9, 1325-1341.
76. Kesik-Brodacka, M., Plucienniczak, G., A universal flu vaccine. Acta Biochim. Pol. 2014, 61, 523-530.
77. Arinaminpathy, N., Ratmann, O., Koelle, K., Epstein, S. L. et al., Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 3173-3177.
78. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W. et al., Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
79. van Gils, M. J., Euler, Z., Schweighardt, B., Wrin, T., Schuitemaker, H., Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009, 23, 2405-2414.
80. Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F. et al., Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341, 1199-1204.
81. Rathore, U., Kesavardhana, S., Mallajosyula, V. V., Varadarajan, R. et al., Immunogen design for HIV-1 and influenza. Biochim. Biophys. Acta 2014, 1844, 1891-1906.
82. Keck, Z. Y., Li, T. K., Xia, J., Gal-Tanamy, M. et al., Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 2008, 82, 6061-6066.
83. Law, M., Maruyama, T., Lewis, J., Giang, E. et al., Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14, 25-27.
84. Tarr, A. W., Owsianka, A. M., Timms, J. M., McClure, C. P. et al., Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43, 592-601.
85. Khan, A. G., Whidby, J., Miller, M. T., Scarborough, H. et al., Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014, 509, 381-384.
86. Kong, L., Giang, E., Nieusma, T., Kadam, R. U. et al., Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013, 342, 1090-1094.
87. Couto, L. B., Kolykhalov, A. A., Animal models for HCV study, in: Tan, S. L. (Ed.) Hepatitis C Viruses: Genomes and Molecular Biology, Norfolk (UK) 2006, pp. 353-372.
88. Norrby, E., Prusiner, S. B., Polio and Nobel prizes: Looking back 50 years. Ann. Neurol. 2007, 61, 385-395.
89. Montagnon, B. J., Polio and rabies vaccines produced in continuous cell lines: A reality for Vero cell line. Dev. Biol. Stand. 1989, 70, 27-47.
90. Omeir, R. L., Teferedegne, B., Foseh, G. S., Beren, J. J. et al., Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp. Med. 2011, 61, 243-250.
91. Doroshenko, A., Halperin, S. A., Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 2009, 8, 679-688.
92. Yang, L. P., Recombinant trivalent influenza vaccine (flublok®): A review of its use in the prevention of seasonal influenza in adults. Drugs 2013, 73, 1357-1366.
93. Cell lines derived from human tumors for vaccine manufacture in: FDA Briefing Document - Vaccines and Related Biological Products Advisory Committee Meeting. 2012, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM319573.pdf.
94. de Groot, R. J., Baker, S. C., Baric, R. S., Brown, C. S. et al., Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J. Virol. 2013, 87, 7790-7792.
95. Rodrigues, A. F., Carrondo, M., Alves, P. M., Coroadinha, A. S., Cellular targets for improved manufacturing of virus-based-biopharmaceuticals. Trends Biotechnol. 2014, 32, 602-607.
96. Graham, F. L., Smiley, J., Russell, W. C., Nairn, R. et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59-74.
97. Katakura, Y., Alam, S., Shirahata, S., Immortalization by gene transfection. Methods Cell Biol. 1998, 57, 69-91.
98. Hehir, K. M., Armentano, D., Cardoza, L. M., Choquette, T. L. et al., Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 1996, 70, 8459-8467.
99. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A. et al., Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 1996, 7, 215-222.
100. Gao, G. P., Engdahl, R. K., Wilson, J. M., A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Hum. Gene Ther. 2000, 11, 213-219.
101. Schiedner, G., Hertel, S., Kochanek, S., Efficient transformation of primary human amniocytes by E1 functions of Ad5: Generation of new cell lines for adenoviral vector production. Hum. Gene Ther. 2000, 11, 2105-2116.
102. Kovesdi, I., Hedley, S. J., Adenoviral producer cells. Viruses 2010, 2, 1681-1703.
103. Genzel, Y., Behrendt, I., Rodig, J., Rapp, E. et al., CAP, a new human suspension cell line for influenza virus production Appl. Microbiol. Biotechnol. 2013, 97, 111-122.
104. Koudstaal, W., Hartgroves, L., Havenga, M., Legastelois, I. et al., Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 2009, 27, 2588-2593.
105. Jordan, I., Vos, A., Beilfuss, S., Neubert, A. et al., An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27, 748-756.
106. Diminsky, D., Schirmbeck, R., Reimann, J., Barenholz, Y., Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): Composition, structure and immunogenicity. Vaccine 1997, 15, 637-647.
107. Fontana, D., Kratje, R., Etcheverrigaray, M., Prieto, C., Rabies virus-like particles expressed in HEK293 cells. Vaccine 2014, 32, 2799-2804.
108. Hua, R. H., Li, Y. N., Chen, Z. S., Liu, L. K. et al., Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate. BMC Biotechnol. 2014, 14, 62.
109. Cox, M. M., Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30, 1759-1766.
110. van Oers, M. M., Pijlman, G. P., Vlak, J. M., Thirty years of baculovirus-insect cell protein expression: From dark horse to mainstream technology. J. Gen. Virol. 2015, 96(Pt1), 6-23.
111. Fernandes, F., Vidigal, J., Dias, M. M., Prather, K. L. et al., Flipase-mediated cassette exchange in Sf9 insect cells for stable gene expression. Biotechnol. Bioeng. 2012, 109, 2836-2844.
112. Tagliamonte, M., Visciano, M. L., Tornesello, M. L., De Stradis, A. et al., HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine 2011, 29, 4913-4922.
113. Marek, M., van Oers, M. M., Devaraj, F. F., Vlak, J. M., Merten, O. W., Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol. Bioeng. 2011, 108, 1056-1067.
114. Chu, C., Lugovtsev, V., Golding, H., Betenbaugh, M., Shiloach, J., Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 14802-14807.
115. Jaluria, P., Betenbaugh, M., Konstantopoulos, K., Frank, B., Shiloach, J., Application of microarrays to identify and characterize genes involved in attachment dependence in HeLa cells. Metab. Eng. 2007, 9, 241-251.
116. Hamamoto, I., Takaku, H., Tashiro, M., Yamamoto, N., High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7. PLoS One 2013, 8, e59892.
117. Li, X., Fan, P., Jin, J., Su, W. et al., Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. Virol. J. 2013, 10, 250.
118. Segura, M. M., Garnier, A., Di Falco, M. R., Whissell, G. et al., Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J. Virol. 2008, 82, 1107-1117.
119. Chezzi, C., Dommann, C. J., Blackburn, N. K., Maselesele, E. et al., Genetic stability of oral polio vaccine prepared on primary monkey kidney cells or Vero cells - effects of passage in cell culture and the human gastrointestinal tract. Vaccine 1998, 16, 2031-2038.
120. El Khoury, A. C., Mast, T. C., Ciarlet, M., Markson, L. et al., Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries. Hum Vaccin. 2011, 7, 506-510.
121. Papaloukas, O., Giannouli, G., Papaevangelou, V., Successes and challenges in varicella vaccine. Ther. Adv. Vaccines 2014, 2, 39-55.
122. Greenberg, R. N., Kennedy, J. S., ACAM2000: A newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs 2008, 17, 555-564.
123. Briggs, D. J., The role of vaccination in rabies prevention. Curr. Opin. Virol. 2012, 2, 309-314.
124. Hens, N., Habteab Ghebretinsae, A., Hardt, K., Van Damme, P., Van Herck, K., Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014, 32, 1507-1513.
125. Bakker, W. A., Thomassen, Y. E., van't Oever, A. G., Westdijk, J. et al., Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29, 7188-7196.
126. Zhang, C., Buchanan, H., Andrews, W., Evans, A., Pass, R. F., Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: Seroconversion and viral shedding. J. Clin. Virol. 2006, 35, 338-342.
127. Coller, B. A., Clements, D. E., Bett, A. J., Sagar, S. L., Ter Meulen, J. H., The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29, 7267-7275.
128. Nolan, T., Roy-Ghanta, S., Montellano, M., Weckx, L. et al., Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: Results of a controlled, randomized efficacy trial J. Infect. Dis. 2014, 210, 545-557.
129. Barouch, D. H., Liu, J., Peter, L., Abbink, P. et al., Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 2013, 207, 248-256.
130. Guy, B., Barrere, B., Malinowski, C., Saville, M. et al., From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29, 7229-7241.
131. Bernstein, D. I., Reap, E. A., Katen, K., Watson, A. et al., Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28, 484-493.
132. Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J. et al., New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 1998, 9, 1909-1917.
133. Kojima, A., Yasuda, A., Asanuma, H., Ishikawa, T. et al., Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J. Virol. 2003, 77, 8745-8755.
134. van Wielink, R., Harmsen, M. M., Martens, D. E., Peeters, B. P. et al., MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres. Vaccine 2011, 29, 6976-6985.